Quinidine-associated skin discoloration in KCNT1-associated pediatric epilepsy

A 9-month-old boy with migrating partial seizures of infancy due to a de novo KCNT1 mutation c.2278A>T (p.Ile760Phe) developed bluish discoloration of the hands, feet, and lips (figure) during a 9-month trial of quinidine (40 mg/kg/d; level 3.4 μg/mL).1 There was no exposure to other medications that cause pigmentary changes. Given minimal improvement in seizures and development, quinidine was stopped. Discoloration persisted at 3 months but markedly improved by the 6-month follow-up. Though common with other potassium channel blockers (ezogabine and quinine), such discoloration has only rarely been reported with quinidine, all in adults.2 Epileptologists should be aware of this potential complication of quinidine therapy.
Source: Neurology - Category: Neurology Authors: Tags: Antiepileptic drugs NEUROIMAGES Source Type: research